Gold prices set for weekly drop as strong dollar weighs; Trump tariffs in focus
SAN JOSE - Anixa Biosciences, Inc. (NASDAQ:ANIX), a $101 million market cap biotechnology company whose stock has surged nearly 40% over the past six months, announced Wednesday that the United States Patent and Trademark Office will issue a new patent covering key aspects of its ovarian cancer vaccine technology on July 15.
The patent (U.S. Patent Number 12,357,593) includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2), which is considered a promising target for ovarian cancer prevention and treatment.
The vaccine technology is being developed through a collaboration between Cleveland Clinic and the National Cancer Institute, focusing on preventing and treating ovarian cancer, particularly among high-risk populations such as individuals with BRCA mutations or family history of the disease.
According to the press release statement, the patent specifically covers methods of administering an immunogenic composition containing a nucleic acid encoding the AMHR2 polypeptide to elicit an AMHR2-specific immune response. The patent was issued to Cleveland Clinic, with Anixa holding exclusive worldwide rights.
"The issuance of this patent by the USPTO continues to strengthen broad protection for the various components and delivery mechanisms of our vaccine technology," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
Anixa’s therapeutic portfolio includes this ovarian cancer vaccine along with other cancer vaccines targeting breast, lung, colon, and prostate cancers. The company’s business model involves partnering with research institutions for technology development and commercialization.
In other recent news, Anixa Biosciences has dosed the first patient in the fourth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. This trial is conducted in collaboration with Moffitt Cancer Center and marks a significant step as the dosage has been increased thirtyfold compared to the first cohort. Meanwhile, H.C. Wainwright has reiterated its Buy rating and a $7.00 price target for Anixa Biosciences, following the completion of enrollment in a Phase 1 trial for the company’s breast cancer vaccine. This trial, supported by the U.S. Department of Defense, has shown promising preliminary results with over 70% of patients demonstrating a protocol-defined immune response.
Additionally, Anixa Biosciences has been granted a Notice of Allowance by the USPTO for a patent related to its breast cancer vaccine technology. This patent, licensed from Cleveland Clinic, is aimed at expanding the range of immunogenic compositions in Anixa’s vaccine portfolio. Dr. Amit Kumar, CEO of Anixa, highlighted the importance of this patent in strengthening the company’s intellectual property. These developments underscore Anixa’s ongoing efforts in cancer treatment and prevention, leveraging collaborations with prominent research institutions like Cleveland Clinic.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.